Liposomal doxorubicin and epirubicin have some differences in adverse reactions and contraindicated people. 1. Adverse reactions: poor appetite, hot flashes, nausea, vomiting, skin rash, amenorrhea and other adverse reactions may occur after the use of epirubicin; while the most common adverse reaction after the use of doxorubicin liposome is myelosuppression, in which leukopenia is the main, anemia and thrombocytopenia can also be seen. 2. Contraindications: epirubicin should not be used in people who are allergic to this drug or other anthracycline drugs, lactating women, obvious bone marrow suppression due to radiotherapy, etc.; doxorubicin liposome should not be used in people who are allergic to the active ingredient of this product or other ingredients, as well as the use of α-interferon to carry out local or systemic treatment of Kaposi’s sarcoma patients with effective, pregnant and lactating women. Patients who need to use doxorubicin liposome or epirubicin should be treated under the guidance of a doctor, and should not blindly treat themselves.